Amryt 
Welcome,         Profile    Billing    Logout  
 3 Products   14 Diseases  3 Products   9 Trials   340 News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Juxtapid (lomitapide) / Novelion, Chiesi
2018-002911-80: Study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia Syndrome Studio per valutare sicurezza, tollerabilità ed efficacia di Lomitapide per il trattamento di pazienti affetti da Sindrome Chilomicronemica Familiare

Ongoing
3
20
Europe
Lojuxta, [C10AX12 Codice ATC], [C10AX12 - Codice ATC], Lojuxta
PRM|21218, Amryt Pharma, Amryt Pharmaceuticals DAC
Familial Chylomicronemia Syndrome Sindrome Chilomicronemica Familiare, Familial hypercholesterolemia is a rare inherited disease that causes high levels of cholesterol in the blood and serious cardiovascular consequences. L'ipercolesterolemia familiare è una rara malattia ereditaria che causa elevati livelli di colesterolo nel sangue e gravi conseguenze cardiovascolari., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2019-002278-30: A clinical trial to assess the safety and effect of the drug lomitapide in the treatment of children with the condition Homozygous Familial Hypercholesterolaemia (HoFH) who are on Stable Lipid-lowering Therapy

Not yet recruiting
3
45
Europe
Lomitapide 2mg hard capsules, [PRD7255830], [PRD7255977], [PRD7256003], [Lomitapide 2mg hard capsules], Capsule, hard, Lojuxta 5 mg hard capsules, Lojuxta 10 mg hard capsules, Lojuxta 20 mg hard capsules
Amryt Pharmaceuticals DAC, Amryt Pharmaceuticals DAC
Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European population., A condition that runs in families (homozygous familial hypercholesterolaemia or HoFH), which leads to the patient having very high cholesterol from a very early age., Body processes [G] - Metabolic Phenomena [G03]
 
 
NCT04681170 / 2019-002278-30: Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Completed
3
46
Europe, RoW
Lomitapide
Amryt Pharma, Amryt Pharmaceuticals DAC
Homozygous Familial Hypercholesterolaemia (HoFH)
10/22
06/24
LILITH, NCT06832371: Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients with Homozygous Familial Hypercholesterolemia

Recruiting
N/A
72
Europe
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi), Amryt Pharmaceuticals DAC, Clinical Trial Consulting, CMV-Stat S.r.l.
Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE), Dyslipidemia
12/26
12/26
NCT02135705: LOWER: Lomitapide Observational Worldwide Evaluation Registry

Checkmark 1-year data from LOWER registry in HoFH at NLA 2016
May 2016 - May 2016: 1-year data from LOWER registry in HoFH at NLA 2016
Recruiting
N/A
300
Europe, Canada, US, RoW
Lomitapide, Juxtapid, Lojuxta
Amryt Pharma
Homozygous Familial Hypercholesterolemia
03/28
09/28
Mycapssa (octreotide) / Chiesi
SWOG-S0518, NCT00569127: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Active, not recruiting
3
427
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Laboratory Biomarker Analysis, Octreotide Acetate, D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt), Longastatin, Longastatina, Mycapssa, Samilstin, Sandostatin, Sandostatin LAR, Sandostatin Lar Depot, Sandostatina, Sandostatine, SMS 201-995, SMS 201-995 AC, Recombinant Interferon Alfa-2b, Alfatronol, Bioferon, Bioferon (TM), Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI)
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
01/15
01/26
2015-001292-51: Follow-Up Study in Patients that Participated in the Chiasma Study CH-ACM-01

Ongoing
3
21
Europe
Octreolin,
Chiasma, Inc., Chiasma, Inc
Acromegaly
 
 
OPTIMAL, NCT03252353 / 2017-000737-31: Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Active, not recruiting
3
56
Europe, Canada, US, RoW
octreotide capsules, MYCAPSSA, Matching placebo, Placebo
Chiasma, Inc.
Acromegaly
06/19
05/22
2010-023895-26: Estudio de prueba de concepto diseñado para evaluar los efectos de Octreolin sobre el gradiente de presión venosa hepática en sujetos con cirrosis e hipertensión portal

Ongoing
2
24
Europe
Octreolin,
Chiasma, Inc.
Cirrosis con signos de hipertensión portal significativa
 
 
Filsuvez (AP101) / Chiesi
REVIVE, NCT06917690: A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

Recruiting
3
6
Japan
Oleogel-S10
Chiesi Farmaceutici S.p.A.
Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional, Skin Abnormalities, Connective Tissue Disease, Collagen Diseases, Skin Diseases, Genetic Diseases, Inborn, Congenital Abnormalities
03/26
09/29
2019-002081-12: A clinical trial to assess the effect of Petrolatum, the vehicle for Oleogel-S10 or, respectively, no treatment on the skin healing process of healthy volunteers with superficial skin wounds.

Not yet recruiting
2
12
Europe
Placebo of Oleogel-S10, Gel, Ointment, ALLERGIKA® – BASISSALBE
Amryt Research Ltd., Amryt Research Ltd.
Not applicable, as healthy volunteers will be recruited, who will receive mechanically induced partial thickness wounds., Not applicable, as healthy volunteers will be recruited, who will receive superficial skin wounds., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2020-002358-26: A clinical trial to assess the effect of petrolatum or, respectively, the vehicle for Oleogel-S10 on the skin healing process of healthy volunteers with superficial skin wounds.

Not yet recruiting
2
16
Europe
Vehicle for Oleogel-S10, Ointment, Gel, ALLERGIKA® – BASISSALBE
Amryt Research Ltd., Amryt Research Ltd.
Not applicable, as healthy volunteers will be recruited, who will receive mechanically induced partial thickness wounds., Not applicable, as healthy volunteers will be recruited, who will receive superficial skin wounds., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05190770: A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

Completed
2
18
US
Triamcinolone Acetonide, Oleogel-S10
Memorial Sloan Kettering Cancer Center
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
08/24
08/24
FOSteR, NCT06423573: A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

Recruiting
N/A
580
Europe
Filsuvez, Birch bark extract
Amryt Pharma, Chiesi Farmaceutici S.p.A.
Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
11/31
08/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Juxtapid (lomitapide) / Novelion, Chiesi
2018-002911-80: Study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia Syndrome Studio per valutare sicurezza, tollerabilità ed efficacia di Lomitapide per il trattamento di pazienti affetti da Sindrome Chilomicronemica Familiare

Ongoing
3
20
Europe
Lojuxta, [C10AX12 Codice ATC], [C10AX12 - Codice ATC], Lojuxta
PRM|21218, Amryt Pharma, Amryt Pharmaceuticals DAC
Familial Chylomicronemia Syndrome Sindrome Chilomicronemica Familiare, Familial hypercholesterolemia is a rare inherited disease that causes high levels of cholesterol in the blood and serious cardiovascular consequences. L'ipercolesterolemia familiare è una rara malattia ereditaria che causa elevati livelli di colesterolo nel sangue e gravi conseguenze cardiovascolari., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2019-002278-30: A clinical trial to assess the safety and effect of the drug lomitapide in the treatment of children with the condition Homozygous Familial Hypercholesterolaemia (HoFH) who are on Stable Lipid-lowering Therapy

Not yet recruiting
3
45
Europe
Lomitapide 2mg hard capsules, [PRD7255830], [PRD7255977], [PRD7256003], [Lomitapide 2mg hard capsules], Capsule, hard, Lojuxta 5 mg hard capsules, Lojuxta 10 mg hard capsules, Lojuxta 20 mg hard capsules
Amryt Pharmaceuticals DAC, Amryt Pharmaceuticals DAC
Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European population., A condition that runs in families (homozygous familial hypercholesterolaemia or HoFH), which leads to the patient having very high cholesterol from a very early age., Body processes [G] - Metabolic Phenomena [G03]
 
 
NCT04681170 / 2019-002278-30: Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Completed
3
46
Europe, RoW
Lomitapide
Amryt Pharma, Amryt Pharmaceuticals DAC
Homozygous Familial Hypercholesterolaemia (HoFH)
10/22
06/24
LILITH, NCT06832371: Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients with Homozygous Familial Hypercholesterolemia

Recruiting
N/A
72
Europe
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi), Amryt Pharmaceuticals DAC, Clinical Trial Consulting, CMV-Stat S.r.l.
Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE), Dyslipidemia
12/26
12/26
NCT02135705: LOWER: Lomitapide Observational Worldwide Evaluation Registry

Checkmark 1-year data from LOWER registry in HoFH at NLA 2016
May 2016 - May 2016: 1-year data from LOWER registry in HoFH at NLA 2016
Recruiting
N/A
300
Europe, Canada, US, RoW
Lomitapide, Juxtapid, Lojuxta
Amryt Pharma
Homozygous Familial Hypercholesterolemia
03/28
09/28
Mycapssa (octreotide) / Chiesi
SWOG-S0518, NCT00569127: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Active, not recruiting
3
427
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Laboratory Biomarker Analysis, Octreotide Acetate, D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt), Longastatin, Longastatina, Mycapssa, Samilstin, Sandostatin, Sandostatin LAR, Sandostatin Lar Depot, Sandostatina, Sandostatine, SMS 201-995, SMS 201-995 AC, Recombinant Interferon Alfa-2b, Alfatronol, Bioferon, Bioferon (TM), Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI)
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
01/15
01/26
2015-001292-51: Follow-Up Study in Patients that Participated in the Chiasma Study CH-ACM-01

Ongoing
3
21
Europe
Octreolin,
Chiasma, Inc., Chiasma, Inc
Acromegaly
 
 
OPTIMAL, NCT03252353 / 2017-000737-31: Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Active, not recruiting
3
56
Europe, Canada, US, RoW
octreotide capsules, MYCAPSSA, Matching placebo, Placebo
Chiasma, Inc.
Acromegaly
06/19
05/22
2010-023895-26: Estudio de prueba de concepto diseñado para evaluar los efectos de Octreolin sobre el gradiente de presión venosa hepática en sujetos con cirrosis e hipertensión portal

Ongoing
2
24
Europe
Octreolin,
Chiasma, Inc.
Cirrosis con signos de hipertensión portal significativa
 
 
Filsuvez (AP101) / Chiesi
REVIVE, NCT06917690: A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

Recruiting
3
6
Japan
Oleogel-S10
Chiesi Farmaceutici S.p.A.
Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional, Skin Abnormalities, Connective Tissue Disease, Collagen Diseases, Skin Diseases, Genetic Diseases, Inborn, Congenital Abnormalities
03/26
09/29
2019-002081-12: A clinical trial to assess the effect of Petrolatum, the vehicle for Oleogel-S10 or, respectively, no treatment on the skin healing process of healthy volunteers with superficial skin wounds.

Not yet recruiting
2
12
Europe
Placebo of Oleogel-S10, Gel, Ointment, ALLERGIKA® – BASISSALBE
Amryt Research Ltd., Amryt Research Ltd.
Not applicable, as healthy volunteers will be recruited, who will receive mechanically induced partial thickness wounds., Not applicable, as healthy volunteers will be recruited, who will receive superficial skin wounds., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2020-002358-26: A clinical trial to assess the effect of petrolatum or, respectively, the vehicle for Oleogel-S10 on the skin healing process of healthy volunteers with superficial skin wounds.

Not yet recruiting
2
16
Europe
Vehicle for Oleogel-S10, Ointment, Gel, ALLERGIKA® – BASISSALBE
Amryt Research Ltd., Amryt Research Ltd.
Not applicable, as healthy volunteers will be recruited, who will receive mechanically induced partial thickness wounds., Not applicable, as healthy volunteers will be recruited, who will receive superficial skin wounds., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05190770: A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

Completed
2
18
US
Triamcinolone Acetonide, Oleogel-S10
Memorial Sloan Kettering Cancer Center
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
08/24
08/24
FOSteR, NCT06423573: A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

Recruiting
N/A
580
Europe
Filsuvez, Birch bark extract
Amryt Pharma, Chiesi Farmaceutici S.p.A.
Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
11/31
08/32

Download Options